Dr. Paul Sax, author of an annual “Really Rapid Review of the Conference on Retroviruses and Opportunistic Infections (CROI),” joins host Eileen Scully to review CROI 2026 abstracts of particular interest to clinicians taking care of patients with HIV.
CROI 2026 abstracts:
Abstracts are cited within the transcript text and those cited are listed below in numerical order, with the abstract number, authors, and title for each. If you attended CROI 2026, you have access to the abstracts online now through the CROI website; if you were not an attendee, check the CROI website late April/early May for access to the abstracts through the CROI searchable abstract database.
- Abstract 126. Kapoor, Y. MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis.
- Abstract 128. Ndlovu, N et al, Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1.
- Abstract 129. Cantos Lucio, VD. Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase.
- Abstract 134. Edgar, J. Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B.
- Abstract 140. Pires Dos Santos, AG., Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT.
- Abstract 142. Haser, G et al., Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy.
- Abstract 177. Rockstroh, JK et al., DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study.
- Abstract 181. Cantos Lucio, VD. Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase.
- Abstract 529. Spinelli, M. et al, Virologic Outcomes After LA ART Initiation With and Without Viremia in 2 Large US Clinic Cohorts.
- Abstract 530. Chan, NY, et al. Week-24 Outcomes of Long-Acting Injectable ART in People With HIV and Suboptimal Viral Suppression.